1292279-01-6Relevant academic research and scientific papers
AZASPIRODECANONE COMPOUNDS
-
Page/Page column 11, (2012/09/25)
The invention provides novel compounds having the general formula (I) wherein R1 and R2 are as described herein, compositions including the compounds, their pharmaceutically acceptable salts and esters and methods of using the compounds.
NEW AZASPIRODECANONE COMPOUNDS
-
Page/Page column 11, (2012/10/08)
The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5 and A are as described herein, compositions including the compounds and methods of using the compounds.
NEW AZASPIRODECANONE COMPOUNDS
-
Page/Page column 28, (2012/10/07)
The invention provides novel compounds having the general formula (I) wherein R1 and R2 are as described herein, compositions including the compounds, their pharmaceutically acceptable salts and esters and methods of using the compou
NEW AZASPIRODECANONE COMPOUNDS AS HSL INHIBITORS
-
Page/Page column 28-29, (2012/10/18)
The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5 and A are as described herein, compositions including the compounds and methods of using the compounds.
SPIRO-CONDENSED CYCLOHEXANE DERIVATIVES AS HSL INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES
-
Page/Page column 257-258, (2011/05/05)
Compounds of formula (I) as well as pharmaceutically acceptable salts thereof can be used in the form of pharmaceutical compositions as HSL inhibitors for the treatment of diabetes, wherein R1,R2, R3, Ca and Cb have the significance given in claim 1.
NEW HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES
-
Page/Page column 81, (2011/05/03)
The present invention relates to compounds of formula (I) as well as pharmaceutically acceptable salts thereof. The are useful as HSL inhibitors and may, for example, be used in treatment of diabetes, metabolic syndrome, dyslipidemia, atherosclerosis, and obesity.
